Loading...
•
Mar 31, 2024
Black Diamond Therapeutics Q1 2024 Earnings Report
Black Diamond Therapeutics reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
Key Takeaways
Black Diamond Therapeutics reported a net loss of $18.2 million for the first quarter of 2024. The company's cash, cash equivalents, and investments totaled $115.2 million as of March 31, 2024, which is expected to fund operations into Q3 2025.
Initiated dosing of patients with non-classical EGFR mutant NSCLC in the first-line setting for BDTX-1535.
On track to release initial Phase 2 results from the ongoing second/third-line cohorts of BDTX-1535 in Q3 2024.
Presented real-world evidence on the evolving EGFR mutation landscape at the 2024 AACR annual meeting.
Cash, cash equivalents, and investments totaled $115.2 million as of March 31, 2024, expected to fund operations into Q3 2025.
Black Diamond Therapeutics
Black Diamond Therapeutics
Forward Guidance
Black Diamond expects that its cash, cash equivalents and investments of $115.2 million will be sufficient to fund its anticipated operating expenses and capital expenditure requirements into the third quarter of 2025.